Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2016 Sep 26;43(6):567–582. doi: 10.1007/s10928-016-9495-8

Figure 3.

Figure 3

Characterization of T-vc-MMAE ADC. (A) Hydrophobic Interaction Chromatography (HIC) analysis of trastuzumab and T-vc-MMAE ADC used for calculation of DAR. (B) Size Exclusion Chromatography (SEC) analysis of trastuzumab and T-vc-MMAE ADC used to assess aggregation in the formulation. (C) Flow cytometry analysis to assess the binding of T-vc-MMAE ADC (in black) and trastuzumab (in dark grey) on HER2 expressing BT474 cells.